Zacks Small-Cap Research's $7 price valuation for ContraFect is based on the clinical success of Exebacase and the advancement of additional Lysin products. Positive clinical results could lead to an increase in the stock price, while negative results may cause a decrease. The valuation will be adjusted based on future clinical results, making this news highly relevant and important for investors in CFRX.